HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Haloxazolam
CS-430 · Somelin · Not found · HALOXAZOLAM · Haloxazo1am · Brn 0569670 · Dea no. 2771 · Haloxazolamum
Identifikatoren & physikalische Daten
| CAS No. | 59128-97-1 |
|---|---|
| Summenformel | C17H14BrFN2O2 |
| Durchschnittliche Molmasse | 377,2 g/mol |
| Monoisotopische Masse | 376,02227 g/mol |
| SMILES | O=C1CN2CCOC2(c2ccccc2F)c2cc(Br)ccc2N1 |
| InChIKey | XDKCGKQHVBOOHC-UHFFFAOYSA-N |
| PubChem CID | 3563 |
| ChEMBL | CHEMBL2104461 |
| ChEBI | CHEBI:31666 |
| DTXSID | DTXSID60866740 |
Chemische & physikalische Eigenschaften
| XLogP | 2,8 |
|---|---|
| Polarare Oberfläche (TPSA) | 41,6 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 1 |
| Schwere Atome | 23 |
| Formalladung | 0 |
| Komplexität | 480 |
| Arzneimittel | DEA NFLIS-Drug Category -> BenzodiazepinesDEA Schedule IV Controlled Substance -> DepressantsPharmaceuticals -> Nervous system -> Anxiolytics |
| Schmelzpunkt | 185° |
| Siedepunkt | 204°C (rough estimate) |
| Dichte | 1.4808 (estimate) |
| pKa (Säurekonstante) | 12.66±0.40(Predicted) |
| NIST chemische Informationen | Haloxazolam(59128-97-1) |
Sicherheit & Vorschriften
| Regulatorische Informationen | DEA schedule IV controlled substance |
|---|---|
| Treatment | General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended. |
| Toxizitätsübersicht | Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| UN-Transportnummer | 3249 |
| Toxizität | LD50 in mice: 1850 mg/kg orally (Kamioka) |
| Gefahrenklasse | 6.1(b) |
| Verpackungsgruppe | III |
| DEA Controlled Substances |
Anwendungen & Verwendung
Verwenden
Sleep-inducing agent, related structurally to Oxazolam and Cloxazolam (C587475). Sedative, hypnotic. Controlled substance (depressant).